Article thumbnail

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

By W G Dixon, K D Watson, M Lunt, L K Mercer, K L Hyrich and D P M Symmons
Topics: Special Articles
Publisher: John Wiley & Sons, Inc.
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.
  2. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published erratum appears in
  3. (2008). American College of Rheumatology
  4. (2006). Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum
  5. (1999). for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet
  6. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis.
  7. How complete and accurate are cancer registrations notified by the National Health Service Central Register for England and Wales?
  8. (1995). Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates.
  9. Malignancy and biologic therapy in rheumatoid arthritis.
  10. (1995). Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum
  11. (1996). Recent progress in the tumor necrosis factor-alpha field. Int Arch Allergy Immunol
  12. (1986). Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis.
  13. The British Society for Rheumatology Biologics Register.
  14. The burden of rheumatoid 762 Dixon et alarthritis and access to treatment: uptake of new therapies.
  15. TNF-alpha in promotion and progression of cancer.
  16. (2003). Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep
  17. (2001). Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of